1 Profitable Stock to Keep an Eye On and 2 We Brush Off

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

A business making money today isn’t necessarily a winner, which is why we analyze companies across multiple dimensions at StockStory. That said, here is one profitable company that balances growth and profitability and two that may face some trouble.

Two Stocks to Sell:

Bristol-Myers Squibb (BMY)

Trailing 12-Month GAAP Operating Margin: 21.7%

With roots dating back to 1887 and a transformative merger in 1989 that gave the company its current name, Bristol-Myers Squibb (NYSE:BMY) discovers, develops, and markets prescription medications for serious diseases including cancer, blood disorders, immunological conditions, and cardiovascular diseases.

Why Do We Think Twice About BMY?

1. Sales were flat over the last two years, indicating it’s failed to expand this cycle
2. Projected sales decline of 3.4% for the next 12 months points to an even tougher demand environment ahead
3. Earnings per share fell by 1.7% annually over the last five years while its revenue grew, showing its incremental sales were much less profitable

Bristol-Myers Squibb is trading at $58.43 per share, or 9.5x forward P/E. Dive into our free research report to see why there are better opportunities than BMY.

Moelis (MC)

Trailing 12-Month GAAP Operating Margin: 17.9%

Founded in 2007 by veteran banker Ken Moelis during the lead-up to the financial crisis, Moelis & Company (NYSE:MC) is an independent investment bank that provides strategic and financial advisory services to corporations, financial sponsors, governments, and sovereign wealth funds.

Why Are We Wary of MC?

1. Incremental sales over the last five years were much less profitable as its earnings per share fell by 3.8% annually while its revenue grew
2. Loan losses and capital returns have eroded its tangible book value per share this cycle as its tangible book value per share declined by 3.5% annually over the last five years

At $62.72 per share, Moelis trades at 18.6x forward P/E. If you’re considering MC for your portfolio, see our FREE research report to learn more.

One Stock to Watch:

Kinder Morgan (KMI)

Trailing 12-Month GAAP Operating Margin: 28.7%

Operating what amounts to the toll roads of the energy industry, Kinder Morgan (NYSE:KMI) transports natural gas, refined petroleum products, and crude oil through its pipeline network across North America.

Why Do We Watch KMI?

1. Unparalleled revenue scale of $17.53 billion gives it advantageous pricing and terms with suppliers
2. EBITDA profits increased over the last five years as the company gained some leverage on its fixed costs and became more efficient
3. Impressive free cash flow profitability enables the company to fund new investments or reward investors with share buybacks/dividends

Kinder Morgan’s stock price of $33.65 implies a valuation ratio of 22.7x forward P/E. Is now a good time to buy? See for yourself in our full research report, it’s free.

High-Quality Stocks for All Market Conditions

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it's flagging for this month - FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.